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[Objectives] Anti-osteoclastic treatments for breast cancer occasionally cause 
medication-related jaw osteonecrosis. Moreover, elevated glycolytic activity, which is 
known as the Warburg effect, is usually observed in these breast cancer cells. Previously, 
we found that cellular communication network factor 2 (CCN2) production and 
glycolysis enhanced each other in chondrocytes. Here, we evaluated the interplay 
between CCN2 and glycolysis in breast cancer cells, as we suspected a possible 
involvement of CCN2 in the Warburg effect in highly invasive breast cancer cells.   
[Methods] Two human breast cancer cell lines with a distinct phenotype were used. 
Glycolysis was inhibited by using 2 distinct compounds and gene silencing was 
performed using siRNA. Glycolysis and the expression of relevant genes were monitored 
via colorimetric assays and quantitative RT-PCR, respectively.  
[Results] Although CCN2 expression was almost completely silenced when treating 
invasive breast cancer cells with a siRNA cocktail against CCN2, glycolytic activity was 
not affected. Notably, the expression of glycolytic enzyme genes, which was repressed 
by CCN2 deficiency in chondrocytes, tended to increase upon CCN2 silencing in breast 
cancer cells. Inhibition of glycolysis, which resulted in the repression of CCN2 expression 
in chondrocytic cells, did not alter or strongly enhanced CCN2 expression in the invasive 
and non-invasive breast cancer cells, respectively.  
[Conclusions] High CCN2 expression levels play a critical role in the invasion and 
metastasis of breast cancer. Thus, a collapse in the intrinsic repressive machinery of CCN2 
due to glycolysis may induce the acquisition of an invasive phenotype in breast cancer 
cells.   
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It is widely recognized that malignant tumors form metastatic lesions in preferred 
tissues and organs, which depend upon the tumor origin [1]. For example, the liver is the 
most common metastasis target of esophageal, gastric, colorectal, and pancreatic cancer 
cells. However, breast and prostate cancers form metastases preferentially in the bone 
tissues, including those in the orofacial region. Bone metastasis of these cancers in the 
orofacial region is a life-threatening complication that severely affects the quality of life 
and orofacial functions of patients. Moreover, even the chemotherapeutics used to control 
these severe complications are known to impair the integrity of orofacial bones, 
particularly the mandibular bone. In order to develop a secondary tumor in the bone tissue, 
metastasizing tumor cells have to remove the calcified bone matrix. Although they can 
degrade extracellular matrix proteins by producing proteases, these cells are not able to 
resorb the calcium phosphate precipitate. Therefore, in order to achieve and progress bone 
metastasis, tumor cells need the cooperation of osteoclasts, as they are the only cells that 
can resorb calcified bone. Thus, the repression of osteoclast activity is one of the major 
strategies employed for the treatment of bone metastases caused by highly metastatic 
breast cancers. Currently, bisphosphonates and neutralizing antibodies against receptor 
activator of NF-κB ligand (RANKL), which is required for osteoclastogenesis, are widely 
used in clinical practice [2,3]. Indeed, these agents have been found to be effective in 
preventing and delaying skeletal-related events, which include bone pain, pathologic 
fractures, spinal cord compression, and hypercalcemia. Particularly in estrogen receptor-
positive breast cancers, these therapeutics are also useful in ameliorating therapy-induced 
bone loss. However, it is now clear that these anti-osteoclastogenic agents occasionally 
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cause an irreversible complication called medication-related osteonecrosis of the jaw 
(MRONJ) [4]. As such, an alternative strategy to repress bone metastasis is necessary, in 
order to protect the oral function of the patients. However, as long as the therapeutic 
targets are limited to osteoclasts, MRONJ may be unavoidable. Thus, a novel strategy 
which targets the tumor cells themselves in order to repress bone metastasis is more 
feasible. For this purpose, more knowledge on the molecular mechanisms that underlie 
the development of a malignant phenotype in breast and prostate cancer cells is required.  
Highly malignant tumor cells, including breast cancer cells, are usually characterized 
by enhanced glycolytic activity, also known as the Warburg effect, which supports the 
aggressive behavior of these cells [5]. This effect was initially observed in the 1920s but 
the underlying mechanism is still unclear. Recently, we discovered that the glycolytic 
activity of chondrocytes, which survive in avascular cartilage tissues, was supported by 
the cellular communication network factor (CCN) 2 [6,7]. CCN2 is a member of the CCN 
family, which contains 6 proteins with multiple functions. The CCN protein family is 
involved in the physiological development of various tissues, as well as pathological 
processes which lead to fibrotic disorders or malignancies [8,9]. In relation to the energy 
metabolism, CCN2 and CCN3 were found to play significant roles, as CCN2 expression 
was repressed, whereas CCN3 expression was strongly induced by glycolytic inhibition 
in chondrocytic cells (Fig. 1A) [10]. Interestingly, strong Ccn3 induction is also observed 
in Ccn2-null mouse chondrocytes [6]. Although the biological significance and cell-type 
specificity of this CCN3 induction are still unclear, CCN2 was clearly shown to contribute 
to glycolysis in chondrocytes. In fact, glycolytic activity and ATP production were 
severely impaired in chondrocytes from Ccn2-null mice, which was also observed in 
CCN2-silenced human chondrocytic HCS-2/8 cells (Fig. 1A) [6]. However, since the 
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metabolic effect of CCN2 was not evaluated in other types of cells, it remains unclear 
whether this a chondrocyte-specific or a general cellular event. Notably, elevated CCN2 
expression levels were observed in a variety of malignancies, including breast cancer 
[8,9,11,12]. Furthermore, CCN2 was reported to play a critical role in the bone-metastatic 
phenotype of breast cancer cells [13-15], suggesting that CCN2 plays a role in the 
aggressive phenotype of breast cancers.  
Although their origin and phenotype are quite different, chondrocytic HCS-2/8 and 
breast cancer MDA-MB-231 cells are both characterized by high CCN2 expression levels. 
Thus, as we suspected that CCN2 may be a factor which drives the development of a 
malignant phenotype in breast cancer cells by inducing the Warburg effect, we 
investigated the interplay between CCN2 and glycolysis in the two cell lines mentioned 
and uncovered a novel regulatory system of CCN2 by glycolysis in breast cancer cells.  
 
 
2. Materials and methods 
 
2.1. Cell cultures 
The MDA-MB-231 cell line is an estrogen-independent breast cancer cell line that is 
characterized by a highly malignant phenotype [16-18]. The other breast cancer cell line 
used, namely MCF7, is known to be less metastatic and retains estrogen dependence [16]. 
These cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) at 37 °C in a 5% CO2 atmosphere. 
 
2.2. Inhibition of glycolysis 
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In order to inhibit glycolysis in the cells, two distinct reagents were employed. One 
is monoiodoacetic acid (MIA), which is an inhibitor of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), while the other is sodium fluoride (NaF), which inhibits 
enolases [19]. MDA-MB-231 and MCF7 cells were seeded in 6-well plates and were 
cultured until confluence. Then, the cells were treated with the respective glycolysis 
inhibitors for 12 h. MIA (Sigma-Aldrich, St. Louis, MO, USA) was added at a final 
concentration of 0, 2 or 4 µg/mL, whereas NaF was used at a final concentration of 0, 1 
or 5 mM. Afterwards, total RNA extraction was extracted from the cells as described 
below. 
 
2.3. Lactate quantification 
Lactate concentrations in the conditioned media from MDA-MB-231 cell cultures 
were quantified using Lactate Colorimetric/Fluorometric Assay Kit (BioVision, Milpitas, 
CA, USA) according to the manufacturer’s instructions. Briefly, the conditioned media 
was diluted in 50 µL of Lactate Assay Buffer in 96-well plates. Enzymatic color 
development was initiated by adding 50 µL of the reaction mixture containing the enzyme 
and colorimetric probe. The reaction was performed at room temperature for 30 min and 
the absorbance was measured at a wavelength of 570 nm using an automated microplate 
reader (Multiscan JX, Thermo Labsystems, Helsinki, Finland).  
 
2.4. RNA extraction and quantitative reverse transcription-polymerase chain reaction 
(RT-PCR) 
Total RNA extraction and purification from cells were performed using an RNeasy® 
Mini Kit (Qiagen, Hilden, Germany) or ISOGEN (Nippongene, Tokyo, Japan), according 
 8 
to the manufacturer’s instructions. Equal amounts of total RNA were reverse-transcribed 
to cDNA using the avian myeloblastosis virus reverse transcriptase with an oligo dT 
primer in the PrimeScriptTM RT reagent Kit (Takara Bio, Shiga, Japan). Subsequently, 
quantitative real-time PCR was performed on a StepOnePlusTM Real-Time PCR System 
(Applied Biosystems, Basel, Switzerland) using the SYBR Green Realtime PCR Master 
Mix (TOYOBO, Osaka, Japan). 
 The following primers were used for the specific amplification of the target cDNAs: 
5ʹ - GCA GGC TAG AGA AGC AGA GC - 3ʹ (forward) and 5ʹ - ATG TCT TCA TGC 
TGG TGC AG - 3ʹ (reverse) for human CCN2; 5ʹ - GGA GCG CGC TAT AAA ACC TG 
- 3ʹ (forward) and 5ʹ - TCC CCT CTC GCT TTT ACC AA - 3ʹ (reverse) for human CCN3; 
5ʹ - CCA AAT GGA ACA CAG AGG ATA AAG - 3ʹ (forward) and 5ʹ - AAC ACT AGG 
TTG ACT TAG GAG CAC - 3ʹ (reverse) for human PGK; 5ʹ - TCT GGA GAC GAT CTT 
ATG ATG TC - 3ʹ (forward) and 5ʹ - AGC TGG TCT TCA GTA AGG TCT GC - 3ʹ 
(reverse) for human PGAM1; 5ʹ - CCA AAG AGG ATC GCC AA - 3ʹ (forward) and 5ʹ - 
CCC CGA ACG ATG AGA CA - 3ʹ (reverse) for human ENO1; and 5ʹ - GAT CAT TGC 
TCC TCC TGA GC - 3ʹ (forward) and 5ʹ - ACT CCT GCT TGC TGA TCC AC - 3ʹ 
(reverse) for human ACTB (β-actin).  
 
2.5. Gene silencing 
For CCN2 silencing via RNAi we used a small interfering RNA (siRNA) cocktail 
composed of 3 distinct siRNAs directed against human CCN2 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), together with a non-targeting control siRNA (Santa Cruz 
Biotechnology). MDA-MB-231 cells were seeded into 12-well plates and transfected at 
sub-confluence with 10 nM of each siRNA using the Lipofectamine® RNAiMAX 
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Reagent (Thermo Fisher Scientific, Carlsbad, CA), according to the manufacturer's 
indications. Forty-eight hours post-transfection, the total cellular RNA was extracted and 
conditioned media were collected from the cell cultures for further analyses. 
 
2.6. Gene Expression Omnibus (GEO) data 
A dataset with the accession number GSE111653 was downloaded from the Gene 
Expression Omnibus (GEO) website (https://www.ncbi.nlm.nih.gov/geo/) at the National 
Center for Biotechnology Information (NCBI). This dataset, which was provided by 
Fertig and Gilkes [17], contains exhaustive RNA sequencing data obtained using the 
Illumina Hiseq 3000/4000 (Illumina, San Diego, CA). The dataset also quantified the 
RNA from both breast cancer and normal mammary epithelial cells. The quality of the 
data was checked by Illumina SAV (Illumina).  
 
2.7. Statistical Analysis 
The statistical comparisons between 2 experimental groups were performed by using 
the Student’s t-test, whereas Tukey's test was employed for multiple comparisons of more 





3.1. The effects of CCN2 silencing on glycolysis and CCN3 expression in MDA-MB-
231 breast cancer cells 
According to our previous studies, CCN2 and glycolysis regulate each other by 
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forming a positive feedback loop in chondrocytes [6,10], which strongly suggests that 
CCN2 could be a key molecule in the development of the Warburg effect (Fig. 1A). 
Therefore, as we suspected that CCN2 played a critical role in the Warburg effect, we 
evaluated the effect of CCN2 silencing on glycolysis in human breast cancer MDA-MB-
231 cells, which are characterized by elevated glycolysis. Thus, by using a siRNA cocktail 
against CCN2, we successfully performed knockdown of CCN2 expression in those cells 
(Fig. 1B). We also confirmed that the non-targeting control siRNA itself did not affect the 
expression of CCN2 (Suppl. Fig. 1). However, we found that lactate production, which 
represents glycolytic activity, was not significantly affected in CCN2-silenced cells (Fig. 
1C). It is known that CCN2 deficiency induces CCN3 expression, as well as impaired 
glycolysis in chondrocytes [20]. This CCN3 induction is thought to be mediated by the 
impairment of glycolytic activity, as glycolysis negatively regulates CCN3 in 
chondrocytes (Fig. 1A) [10]. However, CCN2 deficiency in MDA-MB-231 cells was 
shown to have no effect on CCN3 expression (Fig. 1D), suggesting that CCN2 may not 
regulate glycolysis and/or glycolysis may not regulate CCN3 expression in these cells. To 
further clarify this, MDA-MB-231 cells were treated with MIA, and then CCN3 
expression levels were evaluated. As shown in Fig. 1E, CCN3 expression was increased 
by MIA treatment in a dose-dependent manner, confirming that an active regulatory 
system of CCN3 by glycolysis is also present in breast cancer cells. Collectively, our 
results show that, unlike in chondrocytic cells, glycolysis is not controlled by CCN2 in 
MDA-MB-231 cells.   
 
3.2. The effects of CCN2 silencing on glycolytic enzyme gene expression 
In Ccn2-deficient chondrocytes, the expression of three genes that encode enzymes 
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which catalyze three steps of the glycolysis process was found to be attenuated (Fig. 2A) 
[6,21]. These genes encode phosphoglycerate kinase 1 (PGK1), phosphoglycerate mutase 
1 (PGAM1), and enolase 1 (ENO1). In contrast to the results in chondrocytes, CCN2 
silencing did not affect the expression of these genes and even led to an increase in the 
expression of two out of the three genes (Fig. 2). These results are consistent with those 
shown in Fig. 1, therefore solidly confirming that glycolysis is independent of CCN2 in 
MDA-MB231 cells.   
 
3.3. The effects of glycolysis inhibition on CCN2 expression in breast cancer cells with 
distinct phenotypes 
Next, in order to determine whether CCN2 expression is also positively regulated by 
ATP and/or glycolysis in highly metastatic breast cancer cells, CCN2 expression was 
analyzed in the presence of increasing concentrations of MIA. However, MIA did not 
significantly alter CCN2 expression in MDA-MB-231 cells (Fig. 3A), which indicates 
that CCN2 expression is not positively controlled by glycolysis. As CCN2 expression in 
MDA-MB-231 cells showed a tendency of increase after MIA treatment (Fig. 3A), we 
performed a similar analysis using another breast cancer cell line, MCF7, as we suspected 
that it may have a different CCN2 regulatory system. Surprisingly, CCN2 expression was 
strongly induced upon MIA treatment in a dose-dependent manner, which is opposite to 
the effect found in chondrocytes (Fig. 3B). In order to further confirm that impaired 
glycolysis causes CCN2 induction in MCF7 cells, another glycolysis inhibitor, namely 
NaF, which targets enolase (Fig. 4A), was employed. As expected, NaF also induced 
CCN2 expression in a dose-dependent manner (Fig. 4B). The difference in the CCN2 
regulation by glycolysis could be related to the phenotypic differences between the 2 
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breast cancer cell lines (Fig. 4C). It is well known that hypoxia enhances glycolysis. 
Therefore, we analyzed a dataset of RNA expression profiles from a variety of breast 
cancer and normal mammary epithelial cells exposed to hypoxia, which was available on 
the GEO website. We compared the CCN2 mRNA levels under normoxic and hypoxic 
conditions and found that CCN2 expression was repressed after exposure to 1% O2 for 
24 h in both MCF7 and normal mammary epithelial cells (Fig. 5A). In contrast, hypoxia 
increased CCN2 expression in MDA-MB-231 cells, which is consistent with previous 
findings [22]. These results suggest a mammary epithelial cell-specific negative 
regulation of CCN2, which may be related to the malignant characteristics of breast 





Our previous research on energy metabolism in Ccn2-null mice and human 
chondrocytic cells clearly indicated that CCN2 plays a central role in supporting ATP 
production through glycolysis in chondrocytes [6,20]. Since the cartilage is an avascular 
tissue with a low oxygen supply, these findings were consistent with the notion that 
glycolysis is the dominant energy production system in chondrocytes. Moreover, the 
positive feedback system created via the mutual enhancement of CCN2 and energy 
production should be a critical system used by chondrosarcoma cells (Fig. 5B), including 
the HCS-2/8 cells used in this study, to enhance glycolysis. Therefore, CCN2 can be 
regarded as a Warburg effector, at least in this particular type of tumor. Since the MDA-
MB-231 cell line, which exhibits a prominent Warburg effect, produces higher levels of 
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CCN2 than MCF7, which has a lower glycolytic activity [23], we suspected the 
involvement of the same metabolic system in the Warburg effect in MDA-MB-231 cells. 
However, the results of our study suggest that CCN2 is regulated via a novel system in 
breast cancer cells, which is distinct from the one observed in chondrocytes.   
Previous studies have already revealed that CCN2 is a key molecule involved in 
promoting the bone metastasis of breast cancer cells [12,13]. Kang et al. reported that the 
combination of CCN2 and interleukin 11 (IL-11) drive breast cancer cells to osteolytic 
metastasis [12]. Our study also showed that CCN2 is required for the bone metastasis of 
MDA-MB-231 cells in an animal model in vivo [13]. It should be noted that CCN2 is an 
angiogenesis inducer [24,25] and also enhances matrix metalloproteinase (MMP) 
production [22], which are generally required for the invasion and metastasis of tumors. 
Furthermore, CCN2 was also shown to promote osteoclastogenesis through multiple 
mechanisms [26,27]. This suggests that breast cancer cells are exploiting these functional 
properties of CCN2, rather than its metabolic function, as observed in chondrocytes, in 
order to invade and expand in the bone tissue.  
Another question arising here is how CCN2 production can be constitutively elevated 
in MDA-MB-231 cells in the absence of the positive feedback system found in 
chondrocytes. In this context, the fact that CCN2 gene expression is negatively regulated 
by glycolytic activity in the less invasive MCF7 breast cancer cells (Fig. 3B), while this 
regulation is not observed in MDA-MB-231 cells (Fig. 3A), is of significant importance. 
Based on these findings, we hypothesized that, in less aggressive breast cancer cells and 
possibly, in normal mammary epithelial cells (Fig. 5A), CCN2 is negatively regulated by 
glycolysis (Fig. 5B), while this regulatory system is inactivated in highly metastatic breast 
cancer cells (Fig. 5C). Indeed, this hypothesis is supported by the analysis of the GEO 
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data. Interestingly, MMP-3, which is occasionally produced by breast cancer cells, is 
taken up by the cell and enhances CCN2 expression by acting as a transcription factor 
[28]. This may be another mechanism of CCN2 induction in highly malignant breast 
cancers.  
Breast cancer patients are often treated for bone metastasis using high doses of 
bisphosphonates or antibodies targeting RANKL, which repress bone resorption. This 
strategy is shown to be effective. However, it also exposes the patients to the risk of 
developing MRONJ, a serious oral complication. Although CCN2 may not be associated 
with enhanced energy metabolism in breast cancer cells, this molecule enhances tumor 
angiogenesis and invasion, as well as bone resorption. Therefore, CCN2-targeted 





In chondrocytes, CCN2 and glycolysis support each other by forming a positive 
feedback loop. However, this study revealed that glycolysis is not regulated by CCN2 and 
CCN2 is repressed by glycolysis in breast cancer cells. CCN2 overproduction caused by 
the impairment of this negative regulatory system may drive breast cancer cells to become 
highly invasive.  
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Fig. 1. The effects of CCN2 silencing on glycolysis and its downstream target, CCN3, in 
breast cancer MDA-MB-231 cells. A. Summary of the regulatory network among CCN2, 
CCN3, and glycolysis found in chondrocytes. CCN2 is highly expressed and supports all 
cellular activities by enhancing glycolysis and forming a positive feedback loop with 
glycolysis. B. Efficient CCN2 silencing using a siRNA cocktail in MDA-MB-231 cells. 
Data are represented as the mean and standard deviation (SD) of 3 independent samples. 
C. CCN2 silencing has no effect on lactate production, which represents glycolytic 
activity. Medium lactate concentrations from 6 independent cultures of MDA-MB-231 
cells were measured and compared with those in regular cell cultures. D. CCN2 silencing 
has no effect on CCN3 expression, which is regulated by glycolysis. Mean and SD values 
from 3 independent samples are shown. E. CCN3 is regulated by glycolysis in MDA-
MB-231 cells. The cells from 4 independent cultures were treated with the indicated 
concentrations of monoiodoacetic acid (MIA) for 12 h, following which CCN3 expression 
levels were evaluated. Mean values are shown with error bars for SDs. *p < 0.05, **p < 
0.01; significantly different from the control (NC or 0). The RNA data was standardized 
against the respective ACTB expression level. NC, non-targeting control siRNA.  
 
Fig. 2. The effect of CCN2 deficiency on the gene expression of glycolytic enzymes in 
MDA-MB-231 cells. A. Three genes encoding glycolytic enzymes that are downregulated 
by CCN2 deficiency in murine chondrocytes. The glycolytic steps, which are catalyzed 
by these enzymes, are shown at the top with the relevant metabolites. Genes are 
represented by murine gene symbols. B. CCN2 gene silencing has no effect on the 
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expression of the enzymatic genes PGK1 (left), PGAM1 (center), and ENO1 (right) in 
MDA-MB-231 cells. RNAi-mediated CCN2 silencing was performed under the same 
conditions used in Fig. 1. The relative expression levels standardized using the β-actin 
(ACTB) expression levels are shown. Data represent averages from 3 independent cultures 
with SDs. 
 
Fig. 3. The effects of monoiodoacetic acid (MIA) on CCN2 expression in breast cancer 
MDA-MB-231 (A) and MCF7 (B) cells. The cells were treated with MIA at the indicated 
concentrations for 12 h, after which CCN2 mRNA levels were quantified. The relative 
gene expression levels versus the β-actin (ACTB) expression levels are shown. Mean 
values from 4 independent cell cultures are shown, with error bars representing SDs. ** 
p < 0.01; significantly different from the control (0 µg/mL). 
 
Fig. 4. Negative regulation of CCN2 by glycolysis in the less malignant breast cancer cell 
line, MCF7. A. The distinct glycolytic steps inhibited by monoiodoacetic acid (MIA) and 
sodium fluoride (NaF). B. Dose-dependent induction of CCN2 gene expression by NaF 
in MCF7 cells. The cells were treated with the indicated concentrations of NaF for 12 h, 
following which CCN2 mRNA levels were measured. Values were standardized against 
ACTB mRNA levels. Mean values from 3 independent cell cultures are shown with error 
bars representing SDs. ** p < 0.01; significantly different from the control (0 mM). C. 
Summary of the characteristics of the 2 breast cancer cell lines used in this study.  
 
Fig. 5. A. Hypoxia enhances the effect of glycolysis on CCN2 expression in MCF7, 
human mammary epithelial (HME), and MDA-MB-231 cells. Data are represented as 
 22 
gene counts and were extracted from a quantitative RNA sequencing dataset downloaded 
from the GEO website. H and N indicate the data from the cells cultured in a 1% and 20% 
O2 atmosphere for 24 h, respectively. B. CCN2 is negatively regulated by glycolysis in 
MCF7 cells. CCN2 expression was suppressed by glycolytic activity, which leads to a 
less malignant phenotype. C. Impaired negative regulation of CCN2 by glycolysis in 
MDA-MB-231 cells, which allows CCN2 overproduction for metastasis. The mechanism 
by which glycolysis is overactivated remains unclear. Arrows and T-bar represent positive 




























































































































Fig. 5. Akashi et al.
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